A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after curative hepatic resection or ablation: EMERALD-2.

Journal Article (Journal Article)

Full Text

Duke Authors

Cited Authors

  • Knox, J; Cheng, A; Cleary, S; Galle, P; Kokudo, N; Lencioni, R; Park, J; Zhou, J; Mann, H; Morgan, S; Liu, X; Chin, S; Vlahovic, G; Fan, J

Published Date

  • July 2019

Published In

Volume / Issue

  • 30 Suppl 4 /

Start / End Page

  • iv59 - iv60

PubMed ID

  • 32085222

Electronic International Standard Serial Number (EISSN)

  • 1569-8041

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdz155.216


  • eng

Conference Location

  • England